An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies - PubMed (original) (raw)
Review
An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies
Kerstin Iffland et al. Cannabis Cannabinoid Res. 2017.
Abstract
Introduction: This literature survey aims to extend the comprehensive survey performed by Bergamaschi et al. in 2011 on cannabidiol (CBD) safety and side effects. Apart from updating the literature, this article focuses on clinical studies and CBD potential interactions with other drugs. Results: In general, the often described favorable safety profile of CBD in humans was confirmed and extended by the reviewed research. The majority of studies were performed for treatment of epilepsy and psychotic disorders. Here, the most commonly reported side effects were tiredness, diarrhea, and changes of appetite/weight. In comparison with other drugs, used for the treatment of these medical conditions, CBD has a better side effect profile. This could improve patients' compliance and adherence to treatment. CBD is often used as adjunct therapy. Therefore, more clinical research is warranted on CBD action on hepatic enzymes, drug transporters, and interactions with other drugs and to see if this mainly leads to positive or negative effects, for example, reducing the needed clobazam doses in epilepsy and therefore clobazam's side effects. Conclusion: This review also illustrates that some important toxicological parameters are yet to be studied, for example, if CBD has an effect on hormones. Additionally, more clinical trials with a greater number of participants and longer chronic CBD administration are still lacking.
Keywords: cannabidiol; cannabinoids; medical uses; safety; side effects; toxicity.
Conflict of interest statement
EIHA paid nova-Institute for the review. F.G. is Executive Director of IACM.
Similar articles
- Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
Perry MS. Perry MS. Epilepsy Curr. 2019 Mar-Apr;19(2):93-95. doi: 10.1177/1535759719835671. Epilepsy Curr. 2019. PMID: 30955420 Free PMC article. - Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center.
Porcari GS, Fu C, Doll ED, Carter EG, Carson RP. Porcari GS, et al. Epilepsy Behav. 2018 Mar;80:240-246. doi: 10.1016/j.yebeh.2018.01.026. Epub 2018 Feb 9. Epilepsy Behav. 2018. PMID: 29429908 - Cannabis for the Treatment of Epilepsy: an Update.
Gaston TE, Szaflarski JP. Gaston TE, et al. Curr Neurol Neurosci Rep. 2018 Sep 8;18(11):73. doi: 10.1007/s11910-018-0882-y. Curr Neurol Neurosci Rep. 2018. PMID: 30194563 Review. - Update on Cannabidiol Clinical Toxicity and Adverse Effects: A Systematic Review.
Madeo G, Kapoor A, Giorgetti R, Busardò FP, Carlier J. Madeo G, et al. Curr Neuropharmacol. 2023;21(11):2323-2342. doi: 10.2174/1570159X21666230322143401. Curr Neuropharmacol. 2023. PMID: 36946485 Free PMC article. - Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes.
Chen JW, Borgelt LM, Blackmer AB. Chen JW, et al. Ann Pharmacother. 2019 Jun;53(6):603-611. doi: 10.1177/1060028018822124. Epub 2019 Jan 8. Ann Pharmacother. 2019. PMID: 30616356 Review.
Cited by
- The Potential Role of Cannabidiol in Cosmetic Dermatology: A Literature Review.
Kuzumi A, Yoshizaki-Ogawa A, Fukasawa T, Sato S, Yoshizaki A. Kuzumi A, et al. Am J Clin Dermatol. 2024 Oct 5. doi: 10.1007/s40257-024-00891-y. Online ahead of print. Am J Clin Dermatol. 2024. PMID: 39369127 Review. - Postmarketing Surveillance of Full Spectrum Hemp Extract CBD Products: Reported Adverse Events and Serious Adverse Events.
Kingsbury CM, Zvorsky I, Spelman K. Kingsbury CM, et al. Drugs Real World Outcomes. 2024 Sep 28. doi: 10.1007/s40801-024-00454-x. Online ahead of print. Drugs Real World Outcomes. 2024. PMID: 39340755 - Antiviral effect of cannabidiol on K18-hACE2 transgenic mice infected with SARS-CoV-2.
Polat HU, Yalcin HA, Köm D, Aksoy Ö, Abaci I, Ekiz AT, Serhatli M, Onarici S. Polat HU, et al. J Cell Mol Med. 2024 Sep;28(17):e70030. doi: 10.1111/jcmm.70030. J Cell Mol Med. 2024. PMID: 39267200 Free PMC article. - The neurobehavioural effects of cannabidiol in alcohol use disorder: Study protocol for a double-blind, randomised, cross over, placebo-controlled trial.
Hurzeler TP, Logge W, Watt J, DeMayo MM, Suraev A, McGregor IS, Haber PS, Morley KC. Hurzeler TP, et al. Contemp Clin Trials Commun. 2024 Aug 13;41:101341. doi: 10.1016/j.conctc.2024.101341. eCollection 2024 Oct. Contemp Clin Trials Commun. 2024. PMID: 39252861 Free PMC article. - Cannabidiol exhibits potent anti-cancer activity against gemcitabine-resistant cholangiocarcinoma via ER-stress induction in vitro and in vivo.
Pongking T, Thongpon P, Intuyod K, Klungsaeng S, Thanan R, Chaidee A, Charoenram N, Kongsintaweesuk S, Sakonsinsiri C, Vaeteewoottacharn K, Pinlaor S, Pinlaor P. Pongking T, et al. BMC Complement Med Ther. 2024 Aug 30;24(1):325. doi: 10.1186/s12906-024-04610-2. BMC Complement Med Ther. 2024. PMID: 39215312 Free PMC article.
References
- Bergamaschi MM, Queiroz RH, Zuardi AW, et al. . Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf. 2011;6:237–249 - PubMed
- Grotenhermen F, Müller-Vahl K. Cannabis und Cannabinoide in der Medizin: Fakten und Ausblick. Suchttherapie. 2016;17:71–76
- Deiana S, Watanabe A, Yamasaki Y, et al. . Plasma and brain pharmacokinetic profile of Cannabidiol (CBD), cannabidivarine (CBDV), Delta (9)-tetrahydrocannabivarin (Δ9-THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive compulsive behaviour. Psychopharmacology. 2012;219:859–873 - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources